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Abstract VibraTipTM was selected by the Medical
Technologies Advisory Committee (MTAC) to undergo
evaluation through the National Institute for Health and
Care Excellence (NICE). VibraTipTM provides a vibratory
stimulus for the purpose of detecting diabetic peripheral
neuropathy (DPN) in patients with type 1 or 2 diabetes
mellitus, and is intended to replace the current practice of
using the 128 Hz tuning fork or 10 g monofilament
(comparators). The sponsor (McCallan Medical) provided
clinical and economic submissions which were evaluated
by an External Assessment Centre (EAC). Of six diag-
nostic studies identified, the EAC considered that only one
was directly relevant to the assessment. This study indi-
cated VibraTipTM had a sensitivity of 0.79 (95 % CI
0.69–0.90) and specificity of 0.82 (95 % CI 0.74–0.90) for
DPN using a neurothesiometer at 25 V as a reference
standard. This was non-inferior to the comparators, but the
sample size (n = 141) was too small to draw unequivocal
conclusions and it is unclear how generalisable results were
to clinical practice. The sponsor presented a de facto cost-
minimisation model that in the base case showed minimal
cost savings and, in sensitivity analysis which assumed
diagnostic superiority of VibraTipTM, showed large
savings. The EAC appraised this model and concluded it
was flawed as it was not evidence based and costs were
likely to be unrealistic. The MTAC considered that the
technology showed promise but decided the case for
adoption was not proven, and therefore made a research
recommendation as is reflected in NICE Medical Tech-
nology Guidance 22.
Key Points for Decision Makers
VibraTipTM, intended for the detection of diabetic
peripheral neuropathy (DPN), has advantages in
being readily portable, easy to use and provides a
more consistent stimulus during examination than
the 128 Hz tuning fork.
However, the available published evidence is
insufficient to determine diagnostic superiority or
equivalence of VibraTipTM confidently compared
with the 10 g monofilament or the 128 Hz tuning
fork. Additionally, the device is unlikely to reduce
foot examination costs.
More research is therefore required to establish the
place of VibraTipTM in the diagnostic management
of DPN.
1 Introduction
The National Institute for Health and Care Excellence
(NICE) provides evidence-based guidance for the National
Health Service (NHS) in England and Wales with the aim
of improving clinical outcomes for patients as well as
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delivering optimal use of finite NHS resources. The NICE
Medical Technologies Evaluation Programme (MTEP) was
established in 2009. The aim of MTEP is to evaluate and,
where appropriate, encourage the adoption of, new and
innovative medical devices into the NHS [1].
The Medical Technologies Advisory Committee
(MTAC) is an independent body that works with MTEP
and is responsible for the selection of medical technologies
entering the programme, and the development of guidance
from inception to final recommendations. To be selected,
the technology must hold a current CE (Conformite´ Eur-
ope´enne) mark or be expected to gain one within 12
months, and must be considered by MTEP to have ‘‘plau-
sible promise’’ [2]. This means that the technology must
have the potential to have equivalent benefit to patients at
lower cost to the NHS, or greater benefit with equivalent
costs. Once selected by MTEP and assessment is com-
menced, medical technologies usually undergo a relatively
rapid guidance development process of 38 weeks during
which there is input from the sponsor (usually the manu-
facturer of the technology, who are responsible for sub-
mitting clinical and economic evidence), an External
Assessment Centre (EAC, who evaluate the sponsor’s
claims) and MTAC (who make recommendations) [3].
VibraTipTM (McCallan Medical) is a device resembling
a small key-ring fob that provides a near-silent vibration,
with specified amplitude and frequency similar to that of a
128 Hz calibrated tuning fork. It is indicated for use for the
detection and assessment of diabetic peripheral neuropathy
(DPN) in people with type 1 or type 2 diabetes mellitus.
Adequate management of patients with DPN is believed to
lead to a reduction in the risk of foot ulceration and asso-
ciated complications [4], although good evidence for this,
for instance the effectiveness of patient education inter-
ventions, is lacking [5]. Following MTAC selection of the
topic in September 2013, assessment of VibraTipTM by the
NICE EAC began in February 2014, with final recom-
mendations published in December 2014 (NICE Medical
Technology Guidance MTG22). This article provides an
overview of the sponsor’s submission of evidence, the
EAC’s critique of the evidence, and the formulation of final
guidance. Full documentation of the process, supporting
evidence and the final guidance can be found on the NICE
website [6]. It is one of a series of NICE Medical Tech-
nology Guidance summaries being published in Applied
Health Economics and Health Policy.
2 Background to the Condition and Device
Diabetes (type 1 and type 2) is a chronic disabling condi-
tion that is a major cause of morbidity and mortality, and is
thought to affect around 3.38 million people within the UK
in 2014 [7]. Left untreated, both forms of the disease have
the potential to cause serious complications, including
heart disease, stroke, blindness and nerve damage [8].
Diabetes is also a major burden to the UK economy,
directly costing the UK £9.8 billion in 2010/2011, and this
is forecast to rise to an estimated £16.9 billion by
2035/2036 [9].
Nerve damage caused by diabetes typically manifests
itself as DPN, which is characterised by damage to, or
degeneration of, peripheral nerves of the extremities
including the sensory, motor and autonomic nerves. The
prevalence of DPN in people with diabetes in the UK was
estimated to be 28.5 % in a cross-sectional study
(n = 6487), with higher prevalence associated with type 2
diabetes and greater length of time since onset of diabetes
[10]. Patients with DPN typically have one or more of the
following symptoms: numbness, tingling, pain or weak-
ness. The symptoms typically begin in the feet and spread
proximally, with deterioration of sensory symptoms more
prominent than loss of motor function [11]. If left
untreated, DPN can cause further serious complications.
The main risk is numbness, as minor injuries of the foot
may go unnoticed, leading to ulceration and secondary
infection. In the worst cases, lower-extremity amputation
may be required. Approximately 5 % of people with dia-
betes may develop a foot ulcer in any year, and amputation
rates in diabetic people are around 0.5 % per year [4].
Although the later stages of DPN are poorly reversible
or irreversible [12], there is evidence that improved gly-
caemic control can prevent the appearance and worsening
of polyneuropathy in patients with type 1 diabetes [13], and
although trial evidence is scant, the use of modified foot-
wear and increased vigilance of ulcer formation is uni-
versally recommended for the prevention of foot ulcers in
patients who have DPN [14]. However, to be effective, it is
crucial that preventative measures are undertaken at an
early stage in the development of DPN.
Current NICE clinical guidelines recommend that peo-
ple with diabetes should undergo a thorough foot exami-
nation during their annual review [4, 15]. The foot
examination should include testing of foot sensation (for
DPN); palpation of foot pulses; inspection for any foot
deformity; and inspection of footwear. A combination of
these factors determines whether the person is deemed to
be at low, increased or high risk of foot ulceration, which in
turn informs referral pathways for intensive preventative
management [4]. For people with type 2 diabetes, screen-
ing for the DPN element of the examination should be done
using the 10 g monofilament or vibration (method
unspecified) [4]. For people with type 1 diabetes, a non-
traumatic pin prick is preferred over a vibratory test [15].
VibraTipTM is a new technology that is intended to be a
replacement source of vibratory stimulus.
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3 Decision Problem (Scope)
3.1 Population
The population described in the scope was ‘‘People (adults
and children) with type 1 or 2 diabetes undergoing routine
foot-care checks by health care workers in primary and
secondary care settings’’ [16]. It was noted that diabetes
affects a heterogeneous population, with the incidence and
prevalence of diabetes increasing with age [17], and
therefore caution should be used when generalising results
from specific studies. Additionally, it was clear from the
scope that the use of VibraTipTM by patients on themselves
was out of scope.
3.2 Intervention (VibraTipTM)
The intervention was the VibraTipTM device [16], which is
illustrated in Fig. 1. VibraTipTM produces a vibratory
stimulus similar to that of a 128 Hz tuning fork, and is
intended to be used during examination of the foot for the
detection of DPN. In the scope set by NICE [16], the
sponsor claimed that the benefits of VibraTipTM for
patients would be earlier diagnosis of neuropathy, leading
to improved footcare and subsequent prevention of ulcers
and amputation. For the healthcare system, the claimed
benefits included improved consistency of testing for DPN,
little need for training, greater portability and ease of
cleaning.
Although the description of the intervention as a phys-
ical entity was adequately described, the mode in which
VibraTipTM should be used was not. This is because
although the sponsor stated that VibraTipTM should act as a
direct replacement for the 10 g monofilament or tuning
fork (discussed below), there is currently no universally
accepted guidance or consensus on how these devices
should be used, for instance concerning the number and
location of sites of the foot or feet the devices should be
used on, or how many positive or negative tests should
constitute a provisional diagnosis of DPN. This uncertainty
is likely to impact on the generalisability of diagnostic
accuracy studies to real-life clinical practice.
3.3 Comparators (Current Practice)
Three comparators were listed in the scope. These were the
128 Hz tuning fork, the 10 g monofilament and the bioth-
esiometer [16]. Examples of the 128 Hz tuning fork and the
10 g monofilament are shown in Fig. 1. These devices are
both widely used in NHS primary care, consistent with
NICE guidelines for type 2 diabetes [4], and the Quality
and Outcomes Framework (QoF) [18], which incentivises
general practitioners to undertake DPN screening. The
biothesiometer, which is functionally equivalent to, and has
largely been superseded by, the neurothesiometer, is used
predominantly by specialists, and is frequently the refer-
ence (or ‘gold’) standard used in clinical studies due to its
diagnostic accuracy [19].
3.4 Outcomes
A mixture of diagnostic and management outcomes were
described in the scope. These were sensitivity and speci-
ficity in assessment of vibration perception and/or light
touch; sensitivity and specificity in assessment of grade of
neuropathy; inter-rater agreement of assessment of grade of
neuropathy; accuracy of risk assessment in ulcer formation;
ulcer formation and amputation; time taken for sensory
testing; quality of life and device-related adverse events
[16]. However, only the first of these outcomes was
explored in the clinical studies included in the submission.
4 Review of Clinical Effectiveness Evidence
4.1 Sponsor’s Review of Clinical Effectiveness
Evidence
The sponsor performed a literature search and identified
and presented a total of nine studies that they considered
were relevant to the decision problem. The search identi-
fied seven published papers and two unpublished papers (in
the form of conference posters and abstracts), and the
sponsor excluded one study for not technically being in
scope, leaving a total of eight studies. The literature search
terms were not provided and study selection inclusion and
exclusion criteria were not stated. As it was not replicable,
Fig. 1 Photograph of VibraTipTM, the 10 g monofilament (Bailey’s
Duraban Retractable shown) and the 128 Hz tuning fork (reusable
Gardiner Brown)
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the EAC performed its own literature search to identify
papers published since 2007, following information that the
device was first conceived of in late 2006 [20]. A flow chart
illustrating the EAC’s literature search and sifting of pub-
lished papers is provided in Fig. 2 according to PRISMA
methodology [21], and full details are available on request.
Of the nine studies presented by the sponsor, the EAC
identified eight papers from the literature search, and was
supplied with an additional three unpublished papers from
the sponsor (not identified by the EAC search), making 11
papers in total. Of these papers, the EAC excluded three
papers on the basis one was a review and did not report
additional primary data [22], one was a conference abstract
of a study fully reported elsewhere [23], and one was an
unpublished randomised controlled trial (that has since
been published) but was out of scope on the basis of the
population and intervention studied (lifestyle modification
in people with diagnosed DPN) [24]. Of the eight
remaining papers, two papers were technical studies and
therefore considered out of scope [25, 26]; however, one of
these studies did provide useful technical analysis which
was used in the economic evaluation [26].
The six remaining papers were all cross-sectional
diagnostic accuracy studies and are described in Table 1.
Four were published studies [27–30], one was a confer-
ence abstract [31] and one was a conference poster [32].
These studies informed the clinical evidence submission
for VibraTipTM. The sponsor adequately reported the
characteristics of the relevant studies, but did not criti-
cally appraise the studies to address methodological
quality and potential sources of bias. Although the
sponsor reported the primary results from the studies, they
did not attempt to place the results in the context of the
decision problem.
4.2 Critique of Clinical Effectiveness Evidence
The EAC considered that all six diagnostic accuracy
studies were relevant to the decision problem, and under-
took critical appraisal of these papers to establish their
internal and external validity in this context (Fig. 3). The
EAC used the QUADAS-2 tool (revised Quality Assess-
ment of Diagnostic Accuracy Studies), which assesses the
risk of study bias in four domains (patient selection, index
test, reference standard, flow and timing), and the appli-
cability of the study to the decision problem in three
domains (patient selection, index test and reference stan-
dard) [33], and is recommended by NICE [34].
Fig. 2 PRISMA flow diagram
for the External Assessment
Centre (EAC) literature search
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A significant limitation of three of the studies was the
lack of a reference standard [29, 31, 32], without which it is
impossible to calculate diagnostic accuracy. Another study
was performed in a population who had had DPN pre-
diagnosed, and reported on the target condition of ‘at risk’
feet [27]. This study was considered to be of limited value
because VibraTipTM or its comparators are not routinely
used to detect DPN in this very high-risk population, and it
is not clear how detection of DPN relates to the outcome
reported. Another study used a modified reference standard
(a neurothesiometer set to 20 V rather than the usual
threshold of 25 V) [30]. The difference in vibration per-
ception threshold over this range is likely to be clinically
significant [35] and, for this reason, this study was judged
not to be generalisable to the decision problem.
This left one study, that of Bracewell et al., that was
judged to be most relevant to the decision problem [28].
This study recruited from the most appropriate population
Table 1 Characteristics of six diagnostic accuracy studies that addressed the scope of the decision problem
References Study design Patients and setting Index test(s) Reference test(s) Target condition
Levy [29] Cross-sectional ‘agreement’
study
Patients with diabetes mellitus
undergoing review in hospital
or podiatry clinic (n = 100)
VibraTipTM
10 g
monofilament
128 Hz tuning
fork
None NA
Bowling et al.
[27]
Cross-sectional diagnostic
accuracy study
(additionally,
measurement of ‘intra-
rater reliability’)
Patients with peripheral diabetic
neuropathy (varying severity)
from community and hospital
settings (n = 83)
VibraTipTM (on
hallux only)
Ipswich touch
test
Neurothesiometer
(C25 V
threshold)
(NDS, threshold
C6)
‘At-risk’
neuropathic feet
Bracewell
et al. [23]
Cross sectional diagnostic
accuracy study
Patients with type 1 and 2
diabetes in secondary care
(n = 141)a
VibraTipTM
NeuroTip
10 g
monofilament
128 Hz tuning
fork (hallux
and medial
malleolus
only)
Each performed
in 5 sites on
both feet
Neurothesiometer
(threshold
C25 V)
Peripheral sensory
neuropathy
Urbancic-
Rovan et al.
(conference
abstract)
[31]
Cross-sectional ‘agreement’
study
Patients with diabetes (n = 42) VibraTipTM
10 g
monofilament
128 Hz tuning
fork
Tip Therm
Neuropad
None Diabetic sensory
neuropathy
Garbas et al.
(conference
poster) [32]
Cross-sectional ‘agreement’
study
Patients with diabetes (n = 496) VibraTipTM
128 Hz tuning
fork
None Described as
‘sensory
neuropathy’ and
‘vibration
sensation
impaired’
Nizar et al.
[30]
Cross-sectional diagnostic
accuracy study (diagnostic
case control study)
Patients with type 1 and 2
diabetes recruited from
specialist diabetes clinic
(n = 100)
VibraTipTM
Tuning fork
(oscillation
frequency not
specified)
Neurothesiometer
(20 V threshold)
Diabetic peripheral
neuropathy
NA not applicable, NDS Neuropathy Disability Score
a Plus 18 patients for intra-rater reliability study, of whom 72 % had active or previous ulceration. It is unclear if these patients were included in
the diagnostic accuracy study
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(diabetic patients), used a suitable reference standard
(neurothesiometer set at 25 V) and compared the diagnostic
performance of VibraTipTM with the 10 g monofilament
and the 128 Hz tuning fork (both comparators specified in
the scope). However, a potential weakness of the study was
that it used Receiver Operator Characteristics (ROC) anal-
ysis to optimise the protocol for each device (number of
insensate sites required for DPN detection), and used these
retrospectively to set diagnostic thresholds. Therefore, the
results may not be generalisable to usual clinical practice.
Additionally, although this was the second largest study
identified on VibraTipTM (n = 141), it was likely to have
been underpowered and prone to type 2 error [36].
The results from Bracewell et al. indicated that (relative
to the neurothesiometer), VibraTipTM had a sensitivity of
0.79 (95 % CI 0.69–0.90) and specificity of 0.82 (95 % CI
0.74–0.90); 10 g monofilament had a sensitivity of 0.84
(95 % CI 0.75–0.94) and specificity of 0.83 (95 % CI
0.75–0.91); and the 128 Hz tuning fork had a sensitivity of
0.69 (95 % CI 0.57–0.81) and specificity of 0.90 (95 % CI
0.84–0.97). Thus, the 10 g monofilament was slightly
superior to VibraTipTM in terms of both sensitivity and
specificity, and the 128 Hz tuning fork had poorer sensi-
tivity but superior specificity. Although it was not possible
to perform hypothesis testing because of the way the data
were reported, it is unlikely that there was a statistically
significant difference between the three devices used in this
study. The results of this study are illustrated in Fig. 4.
5 Economic Evidence
5.1 Sponsor’s Economic Submission
There was no indication that the sponsor performed a lit-
erature search for existing economic papers that might
inform the decision problem, and no economic studies were
supplied. However, the EAC did not identify any relevant
economic studies from a subsequent literature search. As is
standard practice for sponsor’s submissions for MTEP [37],
the sponsor provided a de novo economic model to support
claims that VibraTipTM was potentially cost saving to the
NHS.
The model was written and executed in Microsoft
Excel. The basis of the model was that of a decision tree
covering a 3-year time horizon with a starting population of
people with diabetes in the UK (estimated at 2.9 million).
The model had two arms, which consisted of a current
practice arm (10 g monofilament or 128 Hz tuning fork)
and an intervention arm, where patients were tested with
VibraTipTM or retained practice (10 g monofilament or
Fig. 3 Pictogram summary of critical appraisal of diagnostic accuracy studies using QUADAS-2 (revised Quality Assessment of Diagnostic
Accuracy Studies) [bias and applicability domains]
Fig. 4 Sensitivity and false positive rate (1—specificity) of Vibra-
TipTM, 10 g monofilament and the 128 Hz tuning fork (all relative to
a neurothesiometer reference test)
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128 Hz tuning fork). The decision tree simulated patients
on a pathway where they had chances of becoming high
risk for ulceration, developing ulceration, having continued
ulceration or requiring amputation. Each stage in the model
was associated with a transition probability, the number of
patients in that state and the cost of being in that state
(device costs and management costs). The sponsor stated
costs were calculated at present day (2014) values and a
discount rate of 3.5 % was applied.
In the base-case analysis, the sponsor assumed the
VibraTipTM would be used in 40 % of foot examinations.
In addition, the sponsors performed deterministic sensi-
tivity analysis where the usage of VibraTipTM was assumed
to be 20 or 100 %, and this was combined with a second
sensitivity analysis, whereby an assumption was made that
the introduction of VibraTipTM was associated with a 1 %
reduction in ulcer formation (which was applied to the
transitional probabilities used in the decision tree).
The sponsors reported that in the base case, the intro-
duction of VibraTipTM would lead to overall cost savings
to the NHS of approximately £50,000 compared with the
10 g monofilament and £40,000 compared with the 128 Hz
tuning fork. From sensitivity analysis, the sponsor reported
that increased adoption of VibraTipTM would lead to pro-
portionate savings, as would be expected. It was calculated
that if the use of VibraTipTM led to a 1 % reduction in ulcer
formation, then VibraTipTM would lead to savings of
£6,430,000 compared with the 10 g monofilament and
£6,350,000 compared with the 128 Hz tuning fork, at the
level of 40 % adoption.
5.2 Critique of Economic Evidence
The EAC critiqued the sponsor’s economic model, the
accompanying narrative and conclusions. The EAC found
several weaknesses in the model, which was not fully
executable. This, as well as other inconsistencies in the
model’s structure and populated parameters, made it dif-
ficult to replicate the sponsor’s results, as reported in their
narrative, and the veracity of the results could not be
confirmed.
The EAC found that a fundamental weakness of the
model was that there was no diagnostic input into it,
because VibraTipTM and the comparators were assumed to
have diagnostic equivalence. Thus, the clinical evidence
submission did not inform the economic model, and in the
base case the model might be considered a de facto cost
minimisation study, whereby diagnostic equivalence of
devices was assumed with only the costs associated with
device use per examination contributing to the overall
costs. As a consequence of this, the overall cost savings
reported by the sponsor for the base rate were very low
compared with the overall burden of the condition.
The EAC considered that the first sensitivity analysis,
whereby the sponsor adjusted the adoption uptake of
VibraTipTM, which caused a corresponding change in cost
savings in a linear manner, was uninformative. The EAC
considered that the assumption made in the second sensi-
tivity analysis, that use of VibraTipTM would lead to a 1 %
reduction in ulcer formation, had no evidence to support it,
and thus did not inform the decision problem.
5.3 Additional Analysis
The EAC further considered the per examination costs used
by the sponsor for each device, which were the sole drivers
of costs reported in the base-case analysis. For its calcu-
lation of the per examination costs for the 10 g monofila-
ment and the 128 Hz tuning fork, the sponsor used
estimates based on simulated clinic use and expected useful
life (assumed to be 1 year), and had estimated these costs
were 1.0 and 0.8 pence, respectively. However, for
VibraTipTM, the sponsor calculated the per examination
cost according to its battery life, irrespective of simulated
clinical use. The sponsor estimated the per examination
cost would be 0.2 pence, based on 5000 clinical exami-
nations before battery discharge made the device unreli-
able. This was based on a technical paper by Horsfield and
Levy [26]. The EAC considered that this was likely to be
an overestimate and therefore the per examination costs
would likely be higher. This was for two reasons: firstly,
because the technical paper reported that the amplitude of
VibraTipTM decays significantly after the first 1000 acti-
vations, leading the authors to conclude that ‘‘VibraTip
would provide a very consistent source of vibration to test
at least 100 patients, if not considerably more’’; and, sec-
ondly, because the sponsor assumed that only one site on
one foot would be tested. Whilst there is considerable
uncertainty concerning the optimal clinical practice when
testing for DPN, it is anticipated that as a minimum both
feet are tested, but also often multiple sites on each foot.
It is known that the useful life of the 10 g monofilament
is limited, and this issue has been addressed in the litera-
ture. A technical study performed by Lavery et al. on
several brands of monofilaments showed considerable
variation in their durability after repeat testing [38].
However, the Bailey’s 10 g monofilament (used widely in
the NHS [39]) fared comparatively well, with the results
indicating the device produced a buckling force within the
limits of acceptability (between 9 and 11 g) after
1800–2400 tests. If the device is used five times on both
feet (as is suggested in the product literature), this suggests
the Bailey’s monofilament would have a useful life of
approximately 200 patients before requiring replacement.
The EAC considered that, for the 128 Hz tuning fork, it
was not possible to provide a meaningful per examination
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cost in this way, because it has an unlimited useful life. The
per examination costs of VibraTipTM and the 10 g
monofilament (Bailey’s) in various scenarios are reported
in Table 2. As can be seen, in several of these scenarios,
the cost of VibraTipTM (range 0.20–9.95 pence) exceeds
that of the 10 g monofilament (range 3.04–19.00 pence),
with the EAC’s most plausible estimated cost per exami-
nation for VibraTipTM (9.95 pence corresponding to the
published literature) being more than the 10 g monofila-
ment (7.60 pence).
6 NICE Guidance
6.1 Provisional Recommendations and Consultation
In June 2014, MTAC met to make provisional recom-
mendations on VibraTipTM, aided by the EAC and guid-
ance from three expert advisors. During the discussion, the
Committee noted that VibraTipTM had some advantages
over its comparators regarding its portability, ease of use
and ability to produce a consistent stimulus (particularly
compared with the tuning fork, which varies depending on
how hard it is struck). However, it acknowledged that there
was considerable uncertainty regarding the diagnostic
accuracy of the device and the economic case had not been
made. The Committee decided to make a research recom-
mendation that would encourage the development of fur-
ther evidence to support the case for adoption. MTEP plans
to help facilitate this research so the guidance can be
updated when further evidence is available.
Following the meeting, draft guidance was produced,
which was released for public consultation between 9 July
and 8 August 2014. In all, 27 comments were made from
stakeholders, which were addressed at the MTAC meeting
held in October 2014. However, none of the comments
received offered new evidence and, as a result, only minor
word changes were made to the final guidance.
6.2 Final Guidance
In December 2014, NICE made the following recommen-
dations concerning the use of VibraTipTM in patients with
diabetes: [6]
1.1 VibraTipTM shows potential to improve the detection
of DPN and to provide cost savings to the NHS.
Although VibraTipTM appears to be easy to use,
portable and reliable in its functionality, more
evidence is needed on its clinical benefits and
economic advantages to support the case for its
routine adoption in the NHS.
1.2 Research is recommended to address uncertainties in
the potential benefits to patients and the NHS of using
VibraTipTM. Research is needed into the diagnostic
accuracy of VibraTipTM compared with the 10 g
monofilament and calibrated tuning fork in the
diagnosis of peripheral neuropathy in people with
diabetes. This research should also address the
assessment of vibration perception compared with
touch sensation in this clinical context. The research
should gather information on the health system and
Table 2 Per examination cost estimates for VibraTipTM and the 10 g monofilament. Cost estimates for the 128 Hz tuning fork are not possible
using this methodology
Number of activations
in useful lifea
Number of sites per examination (protocol) Cost per examination
(UK pence)
VibraTipTM 5000 1 (hallux on 1 foot, sponsor’s submission) 0.20
5000 2 (hallux on both feet) 0.40
5000 4 (hallux and malleolus on both feet, clinical experts) 0.80
5000 10 (5 sites, both feet [23, 29]) 1.99
1000 1 (hallux on 1 foot, sponsor’s submission) 1.00
1000 2 (hallux on both feet) 1.99
1000 4 (hallux and malleolus on both feet, clinical experts) 3.98
1000 10 (5 sites, both feet [23, 29]) 9.95
Bailey’s 10 g
monofilament
2000 4 (hallux and malleolus on both feet, non-clinical protocol for
direct cost comparison only)
3.04
2000 10 sites (5 sites, both feet, manufacturer’s instructions [38]) 7.60
800 10 sites, ‘‘ worst case scenario’’ reported by Lavery et al. [38] 19.00
Sponsor’s per examination estimate for 10 g monofilament = 1 pence, for 128 Hz tuning fork = 0.8 pence
a 5000 activations is representative of number of activations before battery fails, 1000 is representative of number of activations at consistent
amplitude
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economic impact of introducing VibraTipTM for
detection of DPN. This should include longer-term
outcomes so that an accurate and comprehensive cost
consequences analysis can be carried out. NICE will
review this guidance when substantive new evidence
becomes available.
7 Key Challenges and Learning Points
There were several challenges associated with the devel-
opment of this Medical Technology Guidance (MTG22).
As is common with medical devices, particularly tech-
nologies produced by small manufacturers with limited
access to funding [40], there was a lack of high-quality
clinical studies available, for instance those demonstrating
the diagnostic accuracy of VibraTipTM in comparison with
the 128 Hz tuning fork or 10 g monofilament. Only one
study was identified that matched the scope [28], and this
was underpowered to clearly show non-inferiority of any of
the technologies over another. It is unclear how general-
isable these results are. It is noted that even small differ-
ences in diagnostic accuracy could have major implications
for the subsequent patient pathways, especially when
considered at the population rather than individual level.
An additional area of uncertainty is that currently there
appears to be a large degree of variation in the diagnostic
management of patients at risk of DPN, especially con-
cerning the specific sites of the foot that should be tested,
as well as the number of positive tests (i.e. lack of sensa-
tion) that should facilitate a diagnosis. This level of detail
is not described in existing NICE guidelines [4, 15], and
there appears to be no national or international consensus
regarding the optimal clinical testing protocol.
This lack of unequivocal clinical evidence meant that
the sponsor was compelled to adopt a de facto cost-min-
imisation model for their economic submission. Because
the modelled patient pathways were the same for each
diagnostic technology, only variance in costs between the
technologies themselves contributed to overall cost differ-
ences, but these were trivial in comparison to the overall
burden posed by DPN. The uncertainty in diagnostic clin-
ical practice also contributed to uncertainty regarding the
per examination costs of the economics (Table 2).
The uncertainties surrounding the clinical efficacy of
both VibraTipTM and its comparators, and the impact of
this uncertainty on the economic potential of VibraTipTM,
meant that MTAC were unable to give a clear recom-
mendation about the technology. However, MTAC con-
sidered the technology had promise and so decided to make
a research recommendation that would encourage the
development of further evidence.
8 Conclusion
Following assessment through the MTEP process, the
NICE Medical Technology Guidance 22 describes Vibra-
TipTM as having the potential to improve the detection of
DPN and to provide cost savings for the NHS. However,
there is a lack of available clinical evidence to prove this
beyond reasonable doubt. The research recommendation in
the guidance means that MTEP will try to facilitate the
research so that the guidance can be updated when more
relevant evidence becomes available.
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